+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

CAR T-cell Therapy Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 189 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924697
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The CAR T-cell therapy market is entering a dynamic phase as senior decision-makers guide organizations through rapid technological advancement and growing regulatory complexity. Sustained innovation, changing policy landscapes, and intensifying competition require leaders to stay closely attuned to core trends shaping strategy in the cell therapy ecosystem.

Market Snapshot: CAR T-cell Therapy Market Analysis

The CAR T-cell therapy market is poised for substantial progress, with a projected increase in market value from USD 4.51 billion in 2024 to USD 5.19 billion by 2025. Underscored by a robust compound annual growth rate (CAGR) of 15.06% through 2032, the sector is forecast to achieve a valuation of USD 13.87 billion. Key drivers of this expansion include sustained innovation in cellular engineering, validation from positive clinical trials, and the expansion of therapeutic indications. As prominent industry stakeholders and new entrants compete for influence in a rapidly evolving landscape, deeper market penetration and improved patient outcomes present strategic opportunities for business growth and development.

Scope & Segmentation: Complete Market Coverage

This comprehensive report provides senior executives with actionable data, supporting effective commercial strategy and investment planning across essential segments of the CAR T-cell therapy ecosystem. Strategic decisions are enabled across core market layers:

  • Indications: Acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma—analyzed by current usage and development pipeline trends.
  • Cell Source: Both allogeneic and autologous therapies, rigorously reviewed for scale, clinical maturity, and technology prioritization.
  • Generation: Advancements from first to fourth generation CAR T-cell platforms, with focus on improvements in product performance and applicability.
  • Line of Therapy: Roles in initial and later-line treatment settings are examined, emphasizing patient eligibility and optimal intervention timing.
  • Target Antigen: Includes BCMA and CD19 targeting, covering established methods and new partnership opportunities for technology deployment.
  • End Users: Academic research groups, hospitals, outpatient oncology centers, and specialty clinics, each evaluated by influence on trial generation, treatment delivery, and clinical results.
  • Region: Markets including North America, Latin America, Europe, Middle East, Africa, and Asia-Pacific are detailed to clarify differences in regulatory maturity, R&D investment, and commercial access strategies.
  • Company Coverage: Strategic profiles for Novartis AG, Gilead Sciences, Bristol-Myers Squibb Company, Johnson & Johnson, Legend Biotech Corporation, Miltenyi Biotec GmbH, Allogene Therapeutics, Cellectis S.A., Autolus Therapeutics, and Poseida Therapeutics, with emphasis on collaboration models and innovation direction.

Key Takeaways for Leaders

  • Advances in gene editing and vector technologies fuel progress in individualized and universal CAR T-cell modalities, supporting portfolio diversification and scalable solutions.
  • Improvements in allogeneic processes and automation simplify manufacturing, enabling increased patient access and streamlined operations across geographies.
  • Evolving clinical trial frameworks and regulatory collaboration expedite market introduction of next-generation therapies, reducing time from research to treatment availability.
  • Adaptations in reimbursement models emphasize sustained patient outcomes, affecting partnership structures and pricing arrangements throughout the sector.
  • Distinct geographic strategies are emerging: North America is at the forefront of clinical advancements; EMEA focuses on coordinated patient access; Asia-Pacific accelerates research, development, and commercialization.
  • Strategic partnerships, including contract manufacturing, academic initiatives, and integration of digital health, are critical for alleviating production and operational bottlenecks.

Tariff Impact and Policy Considerations

Recent U.S. tariffs on biopharma components have heightened cost pressures and added to supply chain challenges in CAR T-cell therapy. In response, companies are localizing production, establishing diverse supplier agreements, and optimizing supply networks. Effective navigation of these changes depends on proactive policy engagement and resilient sourcing strategies, enabling continued capacity and market adaptability—despite external policy shifts.

Methodology & Data Sources

Insights are grounded in extensive secondary research from scientific literature, regulatory sources, clinical trial databases, and patent analyses. Primary data was obtained through interviews with oncologists, manufacturing experts, payers, and patient advocates. Findings undergo rigorous triangulation and validation with external subject matter advisors.

Why This Report Matters

  • Enables senior executives to align resources and investments with changing market trends and emerging competitors in CAR T-cell therapy.
  • Supports responsive action to shifts in demand, regulatory requirements, and partnership models for stronger growth and reduced exposure to risk.
  • Anticipates evolving challenges in regulation, logistics, and clinical adoption by providing clarity for better decision-making.

Conclusion

Senior leaders gain a strategic foundation to guide organizational growth, adapt to regional differences, and drive future opportunities. The report delivers the actionable market intelligence necessary to support both resilience and competitiveness in CAR T-cell therapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Expansion of allogeneic off-the-shelf CAR T therapies to broaden patient access
5.2. Emergence of dual-target and armored CAR T constructs for enhanced safety profiles
5.3. Integration of automated manufacturing platforms to reduce CAR T production times
5.4. Implementation of novel gene editing tools to minimize off-target effects in CAR T cells
5.5. Development of combination regimens pairing CAR T-cell therapy with immune checkpoint inhibitors
5.6. Advancements in real-world evidence generation to inform pricing and reimbursement strategies for CAR T
5.7. Regulatory harmonization efforts to accelerate global approval pathways for CAR T-cell treatments
5.8. Adoption of point-of-care manufacturing models within clinical centers to improve treatment accessibility
5.9. Expansion of CAR T-cell therapy indications into solid tumor oncology pipelines worldwide
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. CAR T-cell Therapy Market, by Indication
8.1. Leukemia
8.1.1. Acute Lymphoblastic Leukemia
8.1.2. Acute Myeloid Leukemia
8.2. Multiple Myeloma
8.3. Non Hodgkin Lymphoma
8.3.1. Diffuse Large B Cell Lymphoma
8.3.2. Follicular Lymphoma
8.3.3. Mantle Cell Lymphoma
9. CAR T-cell Therapy Market, by Cell Source
9.1. Allogeneic
9.2. Autologous
10. CAR T-cell Therapy Market, by Generation
10.1. First Generation
10.2. Fourth Generation
10.3. Second Generation
10.4. Third Generation
11. CAR T-cell Therapy Market, by Line Of Therapy
11.1. Frontline
11.2. Relapsed Refractory
12. CAR T-cell Therapy Market, by Target Antigen
12.1. BCMA
12.2. CD19
13. CAR T-cell Therapy Market, by End User
13.1. Academic Research Institutes
13.2. Hospitals
13.3. Outpatient Oncology Centers
13.4. Specialty Clinics
14. CAR T-cell Therapy Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. CAR T-cell Therapy Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. CAR T-cell Therapy Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Gilead Sciences, Inc.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Johnson & Johnson
17.3.5. Legend Biotech Corporation
17.3.6. Miltenyi Biotec GmbH
17.3.7. Allogene Therapeutics, Inc.
17.3.8. Cellectis S.A.
17.3.9. Autolus Therapeutics plc
17.3.10. Poseida Therapeutics, Inc.

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this CAR T-cell Therapy market report include:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Miltenyi Biotec GmbH
  • Allogene Therapeutics, Inc.
  • Cellectis S.A.
  • Autolus Therapeutics plc
  • Poseida Therapeutics, Inc.

Table Information